Eling Pharmaceutical (002603.SZ): Jinlida granules have not yet conducted clinical studies on “weight loss” indications

Gelonghui, April 10 | Eling Pharmaceutical (002603.SZ) said on an interactive platform that Jinlida granules have not conducted clinical research on “weight loss” indications. In 2015, the “Randomized, double-blind, placebo-controlled, multicenter clinical trial of efficacy and safety of metformin monotherapy patients with type 2 diabetes after administration of Jinrida granules” led by the Chinese Academy of Traditional Chinese Medicine Guanganmen Hospital and the University of Chicago Chinese Medicine Research Office, was published in “Plos One” magazine. The results showed that in diet control, exercise therapy, and dimethylbisubin

Gelonghui FinanceApr 10 17:30

Eling Pharmaceutical (002603.SZ): Currently not involved in medical device-related business

Glonghui, December 22|An investor asked Yiling Pharmaceutical (002603.SZ) on the investor interactive platform, “Does your company have any plans to develop in the direction of medical devices?” The company replied that the company is currently not involved in medical device-related business.

Gelonghui FinanceDec 22, 2023 16:17

Yiling Pharmaceutical Gets Nod for China Clinical Trial of Tracheobronchitis Drug

Shijiazhuang Yiling Pharmaceutical (SHE:002603) obtained approval from China's National Medical Products Administration to conduct clinical trials into Lianhua Qingke granules. The pharmaceutical comp

MT NewswiresDec 6, 2023 15:14

Beishui bought SMIC and CNOOC for about HK$200 million each, sold Tencent for over HK$400 million; Nanshui sold CMB for over 300 million yuan

Today, South Capital's net purchase of Hong Kong stocks was HK$348 million. SMIC, CNOOC, and Xiaopeng Motor-W received net purchases of HK$216 million, HK$204 million, and HK$95.36 million respectively; Tencent Holdings, China Mobile, and Ideal Auto -W received net sales of HK$405 million, HK$252 million, and HK$222 million respectively.

Futu NewsNov 27, 2023 17:48

Changes in A-shares | Influenza Infusion Stock, Yiling Pharmaceutical Co., Ltd. has been rising for 3 days, and the registration application for the new drug “Xinqi Nose Tablets” has been accepted

Gelonghui November 27 | Yiling Pharmaceutical (002603.SZ) has been rising for 3 days, now up 3.54% to 26.89 yuan. The stock price hit a new high in nearly half a year, with a total market value of 44.93 billion yuan. Yiling Pharmaceutical recently announced that Beijing Yiling, a wholly-owned subsidiary of the company, has received a “Notice of Acceptance” issued by the State Drug Administration, and that the registration application for the new drug “Xinqi Tongtong Nose Tablets” submitted by Beijing Yiling has been officially accepted. Xinqi Nose Relief Tablets are a Class 1.1 traditional Chinese medicine innovative drug independently developed by the company. Its functional treatment is: it boosts qi, fixes the meter, and strengthens the spleen. It is used for persistent allergic rhinitis, pulmonary insufficiency, and spleen failure. Symptoms include sneezing, runny nose,

Gelonghui FinanceNov 27, 2023 09:44

Yiling Pharmaceutical (002603.SZ): New drug registration application for Xinqi Tongnose tablets accepted

Yiling Pharmaceutical (002603.SZ) announced that Beijing Yiling Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company (“Beijing...

Zhitong FinanceNov 23, 2023 18:52